OPA1 and Photophobia: Treatment with either oral ZOL or ZOL transdermal patches (TPFsp60/6−1:1) significantly reduced NTG-induced photophobia, as predicted from ZOL influence on pain markers (especially CGRP) and pain symptoms, and these results are in accordance with previous studies.